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J. Riethmueller4. 1University of Duisburg-Essen, Dept. of Molecular Biology,
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Introduction: Data on cystic ﬁbrosis mice demonstrate a change of the sphingolipid
metabolism with a massive accumulation of ceramide in the lung, trachea and
gut. Ceramide mediates increased cell death, release of DNA in bronchi, chronic
inﬂammation and increased infection susceptibility to pulmonary P. aeruginosa
infections. Genetic or pharmacological inhibition of ceramide formation employing
Amitriptyline in lungs normalizes all of these pathologies. Amitriptyline inhibits
the acid sphingomyelinase and thus, ceramide release.
Methods: We initiated a phase IIb randomised, double-blind, placebo-controlled
study. Fourty patients were treated with 2×25mg Amitriptyline for 28 days. The
primary endpoint was the change of the lung function parameter FEV1. Secondary
endpoints were decrease of ceramide concentration, pulmonary P. aeruginosa
counts, mucus composition and pro- and anti-inﬂammatory cytokines in sputum.
Results: Amitriptyline was well received in the patient group and only one SAE
was reported in the placebo group. Two well-known AEs of Amitriptyline, i.e.
xerostomia and tiredness, were different between placebo and Amitriptyline, but
occurred only transiently. We found in 37 patients a FEV1 difference of 6.3±11.45%
(p = 0.08) in the ITT analysis and in 29 patients a FEV1 difference of 8.5±10%
(p = 0.013) in the PP analysis.
Conclusion: The Intention-to-treat and per protocol analyses showed a remarkable
primary endpoint difference of FEV1 after 28 days of treatment. These data conﬁrm
the ﬁndings of the previous studies. The results support the notion of a positive
anti-inﬂammatory effect of Amitriptyline therapy in CF-patients.
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Objectives: Two Phase 3 studies were conducted to evaluate ivacaftor in CF subjects
with a G551D mutation. Weight and BMI were evaluated in both studies.
Methods: Both were randomized, double-blind, placebo-controlled studies. Subjects
received placebo or ivacaftor 150mg q12h for 48 weeks plus prescribed therapies.
In STRIVE, 161 subjects with CF 12 years with FEV1 at screening of 40−90%
predicted were dosed. In ENVISION, 52 subjects 6−11 years with FEV1 at
screening of 40–105% predicted were dosed. BMI was adjusted for age and sex
and analyzed as BMI-for-age z-scores in subjects 12 to 20 years in STRIVE and
all subjects in ENVISION.
Results: In STRIVE, 3 placebo and 10 ivacaftor subjects were pancreatic sufﬁcient
(PS). In ENVISION, 1 subject in both groups was PS. The treatment difference
in mean weight change at Week 48 was 2.7 kg (P = 0.0001) in STRIVE and 2.8 kg
(P = 0.0002) in ENVISION. At Week 48, the treatment difference in BMI was
0.9 kg/m2 (P < 0.0001) in STRIVE and 1.1 kg/m2 (P = 0.0003) in ENVISION. In
STRIVE, BMI-for-age z-score in ivacaftor subjects improved to above the 50th
percentile at Week 48. The placebo group worsened over the same period (treatment
difference: 0.33; P = 0.0490). In ENVISION, BMI-for-age z-score improved in
the ivacaftor group. The placebo group worsened to substantially below the 50th
percentile at Week 48 (treatment difference: 0.45; P < 0.0001).
Conclusions: Clinically meaningful improvements in weight and BMI were demon-
strated. These increases were likely not due to the slight imbalance in PS subjects
in STRIVE. There were improvements in BMI-for-age z-scores that achieved the
recommended target in CF nutrition guidelines.
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Objectives: Ivacaftor was evaluated in two 48-week Phase 3 studies. This 96-week
open-label extension (PERSIST) will evaluate the safety and efﬁcacy of long-term
ivacaftor in subjects who completed the prior trials (STRIVE and ENVISION).
Methods: All subjects in PERSIST received ivacaftor 150mg q12h. Here we report
the results of the ﬁrst 12 weeks for subjects who received placebo (n = 67) or
ivacaftor (n = 77) in STRIVE.
Results: The most common AEs reported in PERSIST were pulmonary exacer-
bations, cough, productive cough, upper respiratory tract infection, hemoptysis,
headache, and abdominal pain. 13 (9.0%) subjects had SAEs. The percent predicted
FEV1 improvement observed in subjects treated with ivacaftor during the placebo-
controlled study (STRIVE) was sustained after an additional 12 weeks of ivacaftor
treatment in PERSIST (treatment difference: 9.4 percentage points). In subjects who
had previously received placebo, the percent predicted FEV1 improvement on Day
15 in PERSIST (treatment difference: 10.1 percentage points) was similar to the Day
15 improvement in the ivacaftor group in STRIVE. 8 subjects who received placebo
in STRIVE began PERSIST with an FEV1 <40% predicted. For this subgroup, the
mean (SD) percent predicted FEV1 on Day 1 of STRIVE was 34.5% (3.7%) and
the mean (SD) absolute change on Day 15 was 10.8 (8.7) percentage points and at
Week 12 was 13.0 (10.5) percentage points.
Conclusions: Ivacaftor-related improvements in lung function are sustained over
60 weeks. The response in subjects previously treated with placebo conﬁrms the
effect seen in STRIVE. Ivacaftor appears to have beneﬁcial effects in patients with
severe disease.
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Objectives: Ivacaftor improves FEV1, respiratory symptoms, pulmonary exacerba-
tion risk, and weight gain vs. placebo in subjects with CF 12 years with the G551D
mutation. Since earlier treatment may offer the greatest potential for beneﬁts, this
study was conducted to evaluate the efﬁcacy and safety of ivacaftor in younger
subjects.
Methods: This was a Phase 3, randomized, double-blind, placebo-controlled,
parallel-group, multicenter study. Subjects were 6−11 years with a G551D mutation
and FEV1 40–105% predicted. Subjects received ivacaftor 150mg (n = 26) or
placebo (n = 26) q12h for 48 weeks in addition to prescribed therapies. The dose
had been conﬁrmed in a single dose lead-in PK study.
Results:Mean baseline FEV1 (SD) was 84.2% (18.1%). The treatment effect of iva-
caftor for the primary endpoint, mean absolute change from baseline in % predicted
FEV1 through Week 24, was 12.5% points (P < 0.0001) and through Week 48 was
10.0% points (P = 0.0006). Ivacaftor led to signiﬁcant reduction in sweat chloride,
a measure of improved CFTR activity, through Week 48 (treatment difference:
−53.5mmol/L; P < 0.0001). At Week 48, treatment with ivacaftor resulted in a
signiﬁcant increase in weight (treatment difference: 2.8 kg; P = 0.0002). The most
commonly reported AEs in either arm were respiratory in nature.
Conclusions: Compared to placebo, ivacaftor led to a substantial and statistically
signiﬁcant improvement in pulmonary function, CFTR activity, and weight in this
group of relatively well children. The improvements in FEV1 were comparable to
those seen in the previous study of older children and adults, despite signiﬁcantly
milder disease in this group.
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